EpiCept Corp. (EPCT) Receives Positive Opinion for Adult Leukemia Drug Candidate
EpiCept Corp. (Nasdaq: EPCT) develops drug candidates for the treatment of cancer and pain. The company’s Ceplene compound was designed to combat acute myeloid leukemia (AML), the most common type of leukemia in adults, by protecting lymphocytes that cause the destruction of residual leukemic cells. According to the company, there are roughly 40,000 AML patients in the European Union, with 16,000 new cases occurring each year. The company today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a second opinion regarding the marketing authorization for Ceplene following a request by…